180 Life Sciences, Korro Bio, NuScale Power: Retail Investors Turn Most Bullish On These Stocks

Small-cap stocks like Korro Bio and NuScale Power are benefiting from the momentum generated by larger stocks.
Rising stock prices of 180 Life Sciences, Korro Bio, and NuScale Power fuel bullish retail sentiment on Stocktwits
Rising stock prices of 180 Life Sciences, Korro Bio, and NuScale Power fuel bullish retail sentiment on Stocktwits | Source: Freepik
Profile Image
Prabhjote Gill·Stocktwits
Updated Jul 02, 2025 | 8:31 PM GMT-04
Share this article

180 Life Sciences (ATNF)
180 Life Sciences surged more than 500% on Wednesday becoming the top gainer across U.S. exchanges, boosting retail sentiment.

The sharp rally followed the company’s announcement of its strategic pivot into online gaming, or iGaming, a move that seems to have sent retail investors into a frenzy.

Retail sentiment on Stocktwits has skyrocketed to ‘extremely bullish’ (97/100) from ‘neutral’ a day ago.

Screenshot 2024-10-16 223155.png

NuScale Power Corp. (SMR)

NuScale Power shares surged 33% on Wednesday, buoyed by Amazon's decision to invest in nuclear energy to power its data centers and other facilities at its Washington state headquarters.

NuScale specializes in small modular reactors (SMRs), the same cutting-edge technology Amazon is considering to meet its growing energy demands. The stock soared to an all-time high of $18.01, marking a remarkable 473% year-to-date increase.

Retail sentiment on Stocktwits has dramatically shifted, moving from 'bearish' to 'extremely bullish' (97/100) within a day.

Screenshot 2024-10-16 225310.png

Korro Bio (KRRO)

Korro Bio's shares skyrocketed 111% on Wednesday following Wave Life Sciences’ announcement of early validation for its latest RNA editing technology, a promising breakthrough in the field of genetic medicine.

Korro Bio is heavily investing in RNA editing therapies, specifically targeting Alpha-1 Antitrypsin Deficiency (AATD). The company plans to seek regulatory approval by the end of the year to begin clinical trials for its RNA editing treatments.

Retail sentiment around the company on Stocktwits has been initiated at ‘extremely bullish’ (97/100).

Screenshot 2024-10-16 231152.png

For updates and corrections email newsroom@stocktwits.com.

Subscribe to Trends with Friends
All Newsletters
For serious investors with a serious sense of humor.

Read more: Abbott Labs Stock Dips Pre-Market On Narrowed Profit Outlook: Retail Turns Bearish

Read about our editorial guidelines and ethics policy

Advertisement. Remove ads.